Blood
Articles in this Issue
Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell–type chronic active EBV infection
Abstract Chronic active Epstein-Barr virus (EBV) infection (CAEBV) is an orphan disease characterized by the proliferation and infiltration of EBV-infected T/natural killer (NK) ce...
Molecular clues to venous thromboembolism recurrence
Breaking T-cell tolerance to fight multiple myeloma
Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma
Methylation profiling: unmasking CAEBV’s lymphoma connection
Metabolic adaptation of regenerative hematopoiesis depends on docking-independent mitochondrial connexin 43
Abstract Hematopoietic stem cells (HSCs) exhibit a distinctive antioxidant profile during steady-state and stress hematopoiesis. HSCs and multipotential progenitors (MPPs) are meta...
Artificial intelligence in hematology
Abstract Artificial intelligence (AI) and its subdiscipline, machine learning (ML), have the potential to revolutionize health care, including hematology. The diagnosis and treatme...
Double trouble for a blurry foe: precision strike on BCL11B
Lampson B, Zakharyan A, Shimony SO, Shi H, Deangelo D. Analysis of avapritinib clinical trial data generates a highly accurate predictive model for advanced systemic mastocytosis <i>versus</i> indolent systemic mastocytosis based on peripheral blood testing. <i>Blood.</i> 2024;144(suppl 1):107.
Molecular determinants of thrombosis recurrence risk across venous thromboembolism subtypes
Abstract Venous thromboembolism (VTE) is a frequent (annual incidence of 1-2 per 1000 individuals) and potentially life-threatening (case-fatality rate up to 10%) disease. VTE is a...
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
Abstract Attempting to induce a complete remission before allogeneic hematopoietic cell transplant (alloHCT) is current practice in patients with acute myeloid leukemia (AML). Howe...
AML biology matters, so should we transplant ASAP?
“Connexin” the dots in hematopoietic stem cell potential
Venetoclax plus gilteritinib is effective in preclinical models of <i>FLT3</i> -mutant BCL11B-a lineage-ambiguous leukemia
Abstract Aberrant activation of BCL11B (BCL11B-a) defines a subtype of lineage-ambiguous leukemias with T-lymphoid and myeloid features, co-occurring activating FLT3 mutations, and...
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma
Abstract Cancer vaccines are emerging as promising therapies to not only prevent cancer but to treat cancer. Here, we developed a therapeutic vaccine for multiple myeloma (MM) usin...